Evidence map›Paper›PMID 36142142›Full record

ArticleInternational journal of molecular sciences2022

Multiple Perspectives Reveal the Role of DNA Damage Repair Genes in the Molecular Classification and Prognosis of Pancreatic Adenocarcinoma.

Yujie Li, Ke Zhang, Linjia Peng, Lianyu Chen, Huifeng Gao, Hao Chen

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yujie LiDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0000-0001-7597-9741
Ke ZhangDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Linjia PengDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Lianyu ChenDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0000-0003-3731-8592
Huifeng GaoDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Hao ChenDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0000-0002-5141-2772
Shanghai Medical College of Fudan University · CN

Funding

National Nature Science Foundation of China 81973616
6 · The paper itself

Abstract

Pancreatic adenocarcinoma (PAAD) is a highly heterogeneous and immunosuppressive cancer. This study investigated the diversity of DNA damage repair (DDR) and immune microenvironment in PAAD by transcriptomic and genomic analysis. Patients with PAAD were divided into two DDR-based subtypes with distinct prognosis and molecular characteristics. The differential expression genes were mostly enriched in DDR and immune-related pathways. In order to distinguish high- and low-risk groups clinically, a DDR- and immune-based 5-gene prognostic signature (termed DPRS) was established. Patients in the high-risk group had inferior prognosis, a low level of immune checkpoint gene expression and low sensitivity to DDR-associated inhibitors. Furthermore, single-cell sequencing was used to observe the performance of the DDR-based signature in a high dimension, and immunohistochemistry was used to verify the relationship between the genes we identified and the prognosis of patients with PAAD. In conclusion, the DDR heterogeneity of PAAD was demonstrated, and a novel DDR- and immune-based risk-scoring model was constructed, which indicated the feasibility of DPRS in predicting prognosis and drug response in PAAD patients.

Indexed as

AdenocarcinomaPancreatic NeoplasmsBiomarkers, TumorDNA DamageGene Expression Regulation, NeoplasticHumansTumor MicroenvironmentBiomarkers, TumorDNA damage repairimmunemolecular classificationpancreatic adenocarcinomaprognosis

Identifiers

PMID36142142
PMCPMC9499455
OpenAlexW4295064316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.